单抗KMP1的体内抑制膀胱癌EJ细胞株成瘤的动物实验

杨灿; 巩宇航; 王海峰; 李海皓; 刘靖宇; 王伟; 王剑松; 左毅刚; 陈戬; 詹辉; 丁明霞

单抗KMP1的体内抑制膀胱癌EJ细胞株成瘤的动物实验

昆明医科大学第二附属医院泌尿外科

基金项目:

基金：国家自然科学基金资助项目 (81360376);

计量
- 文章访问数: 2789
- HTML全文浏览量: 1013
- PDF下载量: 91
- 被引次数: 0
出版历程
- 收稿日期: 2017-09-20

The Research of Monoclonal Antibody KMP1 Inhibited Bladder Cancer EJ Cell Lines Growth and Metastasis in Vivo

Funds:

基金：国家自然科学基金资助项目 (81360376);

摘要

摘要: 目的研究膀胱癌单抗KMP1的体内抑制EJ细胞成瘤功能.方法免疫组化鉴定单抗KMP1与EJ、EJ-GFP的结合性, 荧光活体成像观察KMP1的抑制EJ-GFP裸鼠移植瘤的生长状况, 免疫组化和HE染色鉴定移植瘤的肿瘤特征.结果 EJ和EJ-GFP细胞成瘤功能的生长曲线近似, EJ-GFP呈现良好的绿色荧光, EJ和EJ-GFP细胞都能与KMP1结合, 且KMP1治疗组移植瘤重量明显低于m Ig G对照组 (P<0.001) .结论 KMP1能良好的抑制EJ-GFP细胞在裸鼠体内移植瘤生长, KMP1能抑制膀胱癌EJ细胞株体内移植瘤, 是一种可能的靶向治疗药物.
- 膀胱癌 /
- EJ细胞 /
- 单克隆抗体
Abstract: Objective To research the monoclonal antibody KMP1 inhibited bladder cancer EJ cell lines growth and metastasis in vivo by bioluminescence imaging. Me thods Immunohistochemistry was used to determine the KMP1 binding to EJ and EJ-GFP cell lines. The xenograft tumor cell growth and distribution were measured by vernier calipers and dynamic in vivo fluorescence imaging. Immunohistochemistry and H&E counterstaining researched the feature of the xenograft tumor. Re s ults Cell growth curves of EJ and EJ-GFP cells were similar.EJ-GFP had a green fluorescence. In EJ-GFP nude mouse tumor model, the addition of KMP1 significantly inhibited tumor growth and extended the average life span of nude mice. Both EJ and EJ-GFP cells can bind to KMP1, and the weight of transplanted tumors in the KMP1 treatment group was significantly lower than that of the m Ig G control group (P <0.001) .Conclus ion KMP1 has a promising antitumor effect in vivo. It might be valuable for development as a promising targeted agent for bladder cancer.
- Bladder carcinoma /
- EJ cells /
- Monoclonal antibody

HTML全文

参考文献(14)

[1]丁明霞, 李翀, 左毅刚, 等.膀胱癌EJ细胞的CD44异常糖基化及其单抗KMP1的生物学功能研究[J].中国肿瘤临床, 2011, 38 (13) :759-762.
[2]	[2]TORRE L A, BRAY F, SIEGEL R L, et al.Global cancer statistics[J].Cancer Journal for Clinicians, 2015, 65 (2) :87-108.
[3]	[3] FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al.Cancer incidence and mortality worldwide:sources, methods and major patterns in GLOBOCAN 2012[J].International Journal of Cancer Journal International Ducancer, 2015, 136 (5) :E359-386.
[4]	[4]CHEN W, ZHENG R, ZENG H, et al.Annual report on status of cancer in China, 2011[J].Chinese Journal of Cancer Research, 2015, 27 (1) :2-12.
[5]李绍林, 修有成, 刘赞.肌层浸润型膀胱癌治疗的研究进展[J].医学综述, 2018, 24 (5) :911-915.
[6]	[6] SHAH J B, MCCONKEY D J, DINNEY C P.New strategies in muscle-invasive bladder cancer:on the road to personalized medicine[J].Clinical Cancer Research:an Official Journal of the American Association for Cancer Research, 2011, 17 (9) :2608-2612.
[7]	[7]LIGHTFOOT A J, BREYER B N, ROSEVEAR H M, et al.Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer[J].Urol Oncol, 2014, 32 (1) :35.e15-35.e19.
[8]	[8]NEPPLE K G, LIGHTFOOT A J, ROSEVEAR H M, et al.Bacillus Calmette-Guerin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer[J].J Urol, 2010, 184 (5) :1915-1919.
[9]	[9] POWLES T, EDER J P, FINE G D, et al.MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer[J].Nature, 2014, 515 (7528) :558-562.
[10]	[10] PETRYLAK D P, POWLES T, BELLMUNT J, et al.A phase la study of atezolizumab (MPDL-3280A) :updated response and survival data in urothelial bladdercancer (UBC) [J].J Clin Oncol, 2015, 33 (Suppl) ::4501.
[11]丁明霞, 李翀, 左毅刚, 等.CD44 RNAi对EJ细胞增殖、迁移及其与特异性单抗结合力的影响[J].基础医学与临床, 2012, 32 (3) :313-316.
[12]丁明霞, 李翀, 左毅刚, 等.人膀胱癌EJ细胞株CD44基因的小RNA干扰抑制细胞侵袭功能[J].现代泌尿生殖肿瘤杂志, 2012, 3 (6) :345-347.
[13]	[13] DING M X, WANG H F, WANG J S, et al.pp Gal NAc T1as a potential novel marker for human bladder cancer.Asian Pac[J].J Cancer Prev, 2012, 13 (11) :5653-5657.
[14]	[14] BROOKS C L, SCHIETINGER A, BORISOVA SN, et al.Antibody recognition of a unique tumor-specific glycopeptide antigen[J].Proceedings of the National Academy of Sciences of the United States of America, 2010, 107 (22) :10056-10061.

相关文章(20)

[1]	刘胜, 袁飞, 周红庆, 刘明生, 邹东桓, 李钰, 戴子涵, 陈冠宇, 郭峰. 完全性盆底腹膜重建技术在膀胱全切原位新膀胱术中的疗效分析, 昆明医科大学学报.
[2]	刘玉芹, 杨明莹, 王留芳, 夏斯亚, 李丹娜, 赵喜娟, 王娅. 膀胱癌患者报告结局量表的编制与信效度检验, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240727
[3]	安义均, 余立丹, 赵美素, 马冬梅, 杨春花, 孔瑶. 膀胱癌溶酶体相关基因的预后模型构建与分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240510
[4]	谢雨晴, 王俊, 吉学碧, 王萍, 王海峰, 李旭敏, 黄麟雅. 输尿管皮肤造口患者尿路感染危险因素及风险评估研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20231124
[5]	谢峻, 刘绍有, 施鸿金, 毛秋玉, 杨宏. EZH2抑制剂与膀胱癌GC化疗药物联用增敏的作用研究, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20231017
[6]	陈诗, 付什, 谭智勇, 王剑松, 王海峰. 自噬在膀胱癌发展和治疗中的研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230503
[7]	董昊楠, 王海峰, 黄应龙, 施鸿金, 毛岚, 刘毅杰, 王剑松. 根治性膀胱切除原位新膀胱术后代谢并发症及处理研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20221229
[8]	顾君, 何泽喜, 栾婷, 王海峰, 王剑松, 丁明霞. 外泌体长链非编码RNA在膀胱癌中的研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220110
[9]	严植, 郝金钢, 尚芸芸. VI-RADS评分对膀胱癌精准治疗的价值, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220322
[10]	杨媛, 梁红敏, 朱桂敏, 杨寒凝, 曹维涵, 陆永萍. 携IL-6单克隆抗体靶向微泡破坏技术在兔MI/RI损伤中的应用, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210222
[11]	黄宇, 栾婷, 王海峰, 王剑松. 液体活检在监测膀胱癌转移及疗效分析中的研究进展, 昆明医科大学学报.
[12]	李丹娜, 杨明莹, 王俊, 王留芳, 吴光柳, 王会笑, 陈奖国, 姚呈, 黄应龙. 膀胱全切原位尿流改道术患者生命质量下降的术前危险因素, 昆明医科大学学报.
[13]	严勇, 孙洵, 李岗, 郑昕, 马绍翔, 李勇, 赵润恒, 王珂. 膀胱癌患者外周血循环肿瘤细胞中Survivin的表达, 昆明医科大学学报.
[14]	雷玉英, 高洁, 王饶祥, 钏莉雪, 郝金钢. 弥散加权成像在膀胱癌诊断的价值, 昆明医科大学学报.
[15]	胡新一. 3D腹腔镜根治性膀胱切除、回肠原位尿流改道术, 昆明医科大学学报.
[16]	黄振华, 石鑫, 王辉涛, 张劲松, 王光, 郝金刚, 刘建和. 磁共振弥散加权成像在膀胱癌T分期的应用价值, 昆明医科大学学报.
[17]	王红明. 抗人肺鳞癌单克隆抗体的制备和纯化, 昆明医科大学学报.
[18]	马真. 改良型TAT-VP3融合蛋白对膀胱癌BIU-87细胞Bcl-2和Survivin表达的影响, 昆明医科大学学报.
[19]	. 膀胱全切回肠代膀胱术后并发下肢静脉血栓2例护理体会, 昆明医科大学学报.
[20]	. 肌层浸润性膀胱癌的治疗策略, 昆明医科大学学报.